Current progress of RNA aptamer-based therapeutics

Frontiers in Genetics

Volumn 3, Issue NOV, 2012, Pages

  Zhou, Jiehua ^a   Bobbin, Maggie L ^a   Burnett, John C ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

RNA aptamers; RNA interference; Small interfering RNA; Systematic evolution of ligands by exponential enrichment; Targeted delivery

Indexed keywords

EID: 84875171615     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00234     Document Type: Review

References (122)

1. Bagalkot, V., Farokhzad, O. C., Langer, R., and Jon, S. (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45, 8149-8152.
2. Bagalkot,V., and Gao, X. (2011). siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 5, 8131-8139.
3. Baird, G. S., Nelson, S. K., Keeney, T. R., Stewart, A., Williams, S.,Kraemer,S., et al. (2012). Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am. J. Pathol. 180,446-456.
4. Bell, C., Lynam, E., Landfair, D. J., Janjic, N., and Wiles, M. E. (1999). Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro. Cell. Dev. Biol. Anim. 35, 533-542.
5. Bero, A. W., Bauer, A. Q., Stewart, F. R., White, B. R., Cirrito, J. R., Raichle, M. E., et al. (2012). Bidirectional relationship between functional connectivity and amyloid-beta deposition in mouse brain. J. Neurosci. 32, 4334-4340.
6. Blake, C. M., Wang, H., Laskowitz, D. T., and Sullenger, B. A. (2011). A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonu-cleotides 21, 11-19.
7. Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14, 1271-1277.
8. Bunka, D. H., and Stockley, P. G. (2006). Aptamers come of age -at last. Nat. Rev. Microbiol. 4, 588-596.
9. Burnett, J. C., and Rossi, J. J. (2012). RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60-71.
10. Burnett, J. C., Rossi, J. J., and Tiemann, K. (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130-1146.
11. Cerchia, L., Duconge, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., et al. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 3, e123. doi:10.1371/journal.pbio.0030123
12. Chalmers, A. J., Bentzen, S. M., and Buffa, F. M. (2007). A general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of dose. Theor. Biol. Med. Model. 4,25.
13. Chen, C. H., Chernis, G. A., Hoang, V. Q., and Landgraf, R. (2003). Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. U.S.A. 100, 9226-9231.
14. Chen, C. H., Dellamaggiore, K. R., Ouellette, C. P., Sedano, C. D., Lizadjohry, M., Chernis, G. A., et al. (2008). Aptamer-based endocytosis of a lysosomal enzyme. Proc. Natl. Acad. Sci. U.S.A. 105, 15908-15913.
15. Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., et al. (2007). Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869-876.
16. Chiang, H. R., Schoenfeld, L. W., Ruby, J. G., Auyeung, V. C., Spies, N., Baek, D., et al. (2010). Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev. 24, 992-1009.
17. Chu, T. C., Twu, K. Y., Ellington, A. D., and Levy, M. (2006a). Aptamer mediated siRNA delivery. Nucleic Acids Res. 34, e73.
18. Chu, T. C., Marks, J. W., 3rd, Lavery L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., et al. (2006b). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989-5992.
19. Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 469-480.
20. Collis, S. J., Swartz, M. J., Nelson, W G., and Deweese, T. L. (2003). Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 63, 1550-1554.
21. Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F., and Weiss, R. A. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767.
22. Darisipudi, M. N., Kulkarni, O. P., Sayyed, S. G., Ryu, M., Migliorini, A., Sagrinati, C., et al. (2011). Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 179, 116-124.
23. Dassie, J. P., Liu, X. Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27, 839-849.
24. Davidson, B. L., and McCray, P. B. Jr. (2011). Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329-340.
25. Davies, E., and Hiscox, S. (2011). New therapeutic approaches in breast cancer. Maturitas 68,121-128.
26. de Franciscis, V., Esposito, C. L., Catuogno, S., Cellai, L., and Cerchia, L. (2009). Aptamers as innovative diagnostic and therapeutic agents in the central nervous system. CNS Neurol. Disord. Drug Targets 8, 393-401.
27. Demers, G., Meurer, W. J., Shih, R., Rosenbaum, S., and Vilke, G. M. (2012). Tissue plasminogen activator and stroke: review of the literature for the clinician. J. Emerg. Med. PMID:22818644. [Epub ahead of print].
28. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., et al. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
29. Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., and Lippard, S. J. (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 105,17356-17361.
30. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999). The glutamate receptor ion channels. Pharmacol. Rev. 51,7-61.
31. Dua, P., Kim, S., and Lee, D. K. (2011). Nucleic acid aptamers targeting cell-surface proteins. Methods 54,215-225.
32. Duyster, J., Bai, R. Y., and Morris, S. W. (2001). Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20, 5623-5637.
33. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). Duplexes of 21 -nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411,494-498.
34. Ellington, A. D., and Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
35. Esposito, C. L., Passaro, D., Longobardo, I., Condorelli, G., Marotta, P., Affuso, A., et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6, e24071. doi:10.1371/journal.pone.0024071
36. Farokhzad, O. C. (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64, 7668-7672.
37. Farokhzad, O. C. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. U.S.A 103,6315-6320.
38. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
39. Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., et al. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U.S.A. 105,2586-2591.
40. Guo, P. (2010). The emerging field of RNA nanotechnology. Nat. Nanotechnol. 5, 833-842.
41. Guo, S., Tschammer, N., Mohammed, S., and Guo, P. (2005). Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum. Gene Ther. 16, 1097-1109.
42. Hicke, B. J., Marion, C., Chang, Y. F., Gould, T., Lynott, C. K., Parma, D., et al. (2001). Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276, 48644-48654.
43. Hicke, B. J., Stephens, A. W., Gould, T., Chang, Y. F., Lynott, C. K., Heil, J., et al. (2006). Tumor targeting by an aptamer. J. Nucl. Med. 47, 668-678.
44. Higa, G. M., Singh, V., and Abraham, J. (2010). Biological considerations and clinical applications of new HER2-targeted agents. Expert Rev. Anticancer Ther. 10, 1497-1509.
45. Higuchi, Y., Kawakami, S., and Hashida, M. (2010). Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24,195-205.
46. Huang, J., Moore, J., Soffer, S., Kim, E., Rowe,D.,Manley,C.A.,etal. (2001). Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. 36, 357-361.
47. Huang,Z.,Pei,W.,Han,Y.,Jayaseelan,S., Shekhtman,A.,Shi, H.,etal. (2009). One RNA aptamer sequence, two structures: a collaborating pair that inhibits AMPA receptors. Nucleic Acids Res. 37, 4022-4032.
48. Hussey, R. E., Richardson, N. E., Kowalski, M., Brown, N. R., Chang, H. C., Siliciano, R. F., et al. (1988). A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 331, 78-81.
49. Ishiguro, A., Akiyama, T., Adachi, H., Inoue, J., and Nakamura, Y. (2011). Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum. 63, 455-466.
50. Jeong, S., Eom, T., Kim, S., Lee, S., and Yu, J. (2001). In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion. Biochem. Biophys. Res. Commun. 281,237-43.
51. Kang, K. N., and Lee, Y. S. (2012). RNA aptamers: a review of recent trends and applications. Adv. Biochem. Eng. Biotechnol. PMID:22491855. [Epub ahead of print].
52. Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., et al. (1993). Uniformly modified 2/-deoxy-2/-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36,831-841.
53. Keefe, A. D., Pai, S., and Ellington, A. (2010). Aptamers as therapeutics. Nat. Rev. DrugDiscov. 9, 537-550.
54. Khaled, A., Guo, S., Li, F., and Guo, P. (2005). Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett. 5, 1797-1808.
55. Kim, E., Jung, Y., Choi, H., Yang, J., Suh, J. S., Huh, Y M., et al. (2010). Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31,4592-4599.
56. Kraus, E., James, W., and Barclay, A. N. (1998). Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function.J. Immunol. 160,5209-5212.
57. Kurreck, J. (2009). RNA interference: from basic research to therapeutic applications. Angew. Chem. Int. Ed. Engl. 48,1378-1398.
58. Lee, I. H., An, S., Yu, M. K., Kwon, H. K., Im, S. H., and Jon, S. (2011). Targeted chemoim-munotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release 155,435-441.
59. Lee, Y J., and Lee, S. W. (2012). Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein. Biochem. Biophys. Res. Commun. 417,521-527.
60. Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R., and Farokhzad, O. C. (2008). Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 26, 442-449.
61. Li, N., Larson, T., Nguyen, H. H., Sokolov, K. V., and Ellington, A. D. (2010). Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. (Camb.) 46, 392-394.
62. Li, N., Nguyen, H. H., Byrom, M., and Ellington, A. D. (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6, e20299. doi:10.1371/journal.pone.0020299
63. Lindvall, O., and Kokaia, Z. (2006). Stem cells for the treatment of neurological disorders. Nature 441, 1094-1096.
64. Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., et al. (1998). Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58, 4055-4060.
65. Lorger, M., Engstler, M., Homann, M., and Goringer, H. U. (2003). Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. Eukaryotic Cell 2, 84-94.
66. Lupold, S. E., Hicke, B. J., Lin, Y., and Coffey, D. S. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033.
67. Mann, A. P., Bhavane, R. C., Somasunderam, A., Liz Montalvo-Ortiz, B., Ghaghada, K. B., Volk, D., et al. (2011). Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2,298-304.
68. Mann, A. P., Somasunderam, A., Nieves-Alicea, R., Li, X., Hu, A., Sood, A. K., et al. (2010). Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS ONE 5, e13050. doi:10.1371/journal.pone.00 13050
69. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., et al. (2001). beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 12245-12250.
70. Mayer, G. (2009). The chemical biology of aptamers. Angew. Chem. Int. Ed. Engl. 48, 2672-2689.
71. McNamara, J. O. II., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015.
72. Min, K., Jo, H., Song, K., Cho, M., Chun, Y. S., Jon, S., et al. (2011). Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 32, 2124-2132.
73. Moasser, M. M. (2007). Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26, 6577-6592.
74. Mori, T., Oguro, A., Ohtsu, T., and Nakamura, Y (2004). RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res. 32, 6120-6128.
75. Murakami, K., Nishikawa, F., Noda, K., Yokoyama, T., and Nishikawa, S. (2008). Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its beta isoform with high affinity. Prion 2, 73-80.
76. Muramatsu, T. (2011). Midkine: a promising molecule for drug development to treat diseases of the central nervous system. Curr. Pharm. Des. 17,410-423.
77. Ng, E. W., Shima, D. T., Calias, P., Cunningham, E. T. Jr., Guyer, D. R., and Adamis, A. P. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. DrugDiscov. 5,123-132.
78. Ni, X., Castanares, M., Mukherjee, A., and Lupold, S. E. (2011a). Nucleic acid aptamers: clinical applications and promising new horizons. Curr. Med. Chem. 18,4206-4214.
79. Ni, X., Zhang, Y., Ribas, J., Chowdhury, W. H., Castanares, M., Zhang, Z., et al. (2011b). Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumorxenografts. J. Clin. Invest. 121, 2383-2390.
80. Nimjee, S. M., Rusconi, C. P., and Sullenger, B. A. (2005). Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583.
81. Ohnishi, K., Scuric, Z., Schiestl, R. H., Okamoto, N., Takahashi, A., and Ohnishi, T. (2006). siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat. Res. 166, 454-462.
82. Park, J. S., Wang, C., Han, Y., Huang, Z., and Niu, L. (2011). Potent and selective inhibition of a single alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit by an RNA aptamer. J. Biol. Chem. 286, 15608-15617.
83. Pastor, F., Kolonias, D., Giangrande, P. H., and Gilboa, E. (2010). Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465, 227-230.
84. Pelchen-Matthews, A., Armes, J. E., Griffiths, G., and Marsh, M. (1991). Differential endocytosis of CD4 in lym-phocytic and nonlymphocytic cells. J. Exp. Med. 173, 575-587.
85. Proske, D., Gilch, S., Wopfner, F., Schatzl, H. M., Winnacker, E. L., and Famulok, M. (2002). Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 3, 717-725.
86. Rahimi, F., and Bitan, G. (2010). Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease. J. Vis. Exp. doi:10.3791/1955
87. Rahimi, F., Murakami, K., Summers, J. L., Chen, C. H., and Bitan, G. (2009). RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity. PLoS ONE 4, e7694. doi:10.1371/journal.pone.0007694
88. Rentmeister, A., Bill, A., Wahle, T., Walter, J., and Famulok, M. (2006). RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 in vitro. RNA 12, 1650-1660.
89. Rhie, A., Kirby, L., Sayer, N., Wellesley, R., Disterer, P., Sylvester, I., et al. (2003). Characterization of 2/-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Biol. Chem. 278, 39697-39705.
90. Roth, F., De La Fuente, A. C., Vella, J. L., Zoso, A., Inverardi, L., and Serafini, P. (2012). Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 72, 1373-1383.
91. Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., et al. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94.
92. Sanghvi, Y. S. (2011). A status update of modified oligonucleotides for chemotherapeutics applications. Curr. Protoc. Nucleic Acid Chem. 4, 1-22.
93. Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., and Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63, 7483-7489.
94. Sayyed, S. G., Hagele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., et al. (2009). Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomeruloscle-rosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52,2445-2454.
95. Scott, A. M., Wolchok, J. D., and Old, L. J. (2012). Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287.
96. Sherr, C. J. (1996). Cancer cell cycles. Science 274, 1672-1677.
97. Shu, Y., Cinier, M., Shu, D., and Guo, P. (2011). Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods 54,204-214.
98. Sundaresan, S., Penuel, E., and Sliwkowski, M. X. (1999). The biology of human epidermal growth factor receptor 2. Curr. Oncol. Rep. 1, 16-22.
99. Syed, M. A., and Pervaiz, S. (2010). Advances in aptamers. Oligonucleotides 20,215-224.
100. Tan, W., Wang, H., Chen, Y., Zhang, X., Zhu,H.,Yang, C., etal. (2011). Molecular aptamers for drug delivery. Trends Biotechnol. 29, 634-640.
101. Tasch, J., Gong, M., Sadelain, M., and Heston, W. D. (2001). A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol. 21,249-261.
102. Thiel, K. W., and Giangrande, P. H. (2009). Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19, 209-222.
103. Thiel, K. W., and Giangrande, P. H. (2010). Intracellular delivery of RNA-based therapeutics using aptamers. Ther. Deliv. 1, 849-861.
104. Thiel, K. W., Hernandez, L. I., Dassie, J. P., Thiel, W H., Liu, X., Stockdale, K. R., et al. (2012). Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 40, 6319-6337.
105. Tolentino, M. (2011). Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv. Ophthalmol. 56, 95-113.
106. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
107. Vinores, S. A. (2006). Pegaptanib in the treatment of wet, age-related macular degeneration. Int. J. Nanomedicine 1,263-268.
108. Wang, A. Z., Bagalkot, V., Vasilliou, C. C., Gu, F., Alexis, F., Zhang, L., et al. (2008a). Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem.3, 1311-1315.
109. Wang, J., Takeuchi, H., Sonobe, Y., Jin, S., Mizuno, T., Miyakawa, S., et al. (2008b). Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc. Natl. Acad. Sci. U.S.A. 105,3915-3920.
110. Wang, Y., Khaing, Z. Z., Li, N., Hall, B., Schmidt, C. E., and Ellington, A. D. (2010). Aptamer antagonists of myelin-derived inhibitors promote axon growth. PLoS ONE 5, e9726. doi:10.1371/journal.pone.0009726
111. Whitehead, K. A., Langer, R., and Anderson, D. G. (2009). Knocking down barriers: advances in siRNA delivery. Nat. Rev. DrugDiscov. 8, 129-138.
112. Wu, X., Ding, B., Gao, J., Wang, H., Fan, W., Wang, X., et al. (2011). Second-generation ap tamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int. J. Nanomedicine 6,1747-1756.
113. Wullner, U., Neef, I., Eller, A., Kleines, M., Tur, M. K., and Barth, S. (2008). Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets 8, 554-565.
114. Yamashita, T., and Tohyama, M. (2003). The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci. 6,461-467.
115. Yang, J., Xie, S. X., Huang, Y., Ling, M., Liu, J., Ran, Y., et al. (2012). Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond). 7,1297-1309.
116. Yarden, Y (2001). Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2), 1-13.
117. Ylera, F., Lurz, R., Erdmann, V. A., and Furste, J. P. (2002). Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem. Biophys. Res. Commun. 290, 1583-1588.
118. Zhang, L., Radovic-Moreno, A. F., Alexis, F., Gu, E X., Basto, P. A., Bagalkot, V., et al. (2007). Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer biocon-jugates. ChemMedChem. 2, 1268-1271.
119. Zhang, P., Zhao, N., Zeng, Z., Feng, Y., Tung, C. H., Chang, C. C., et al. (2009). Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab. Invest. 89, 1423-1432.
120. Zhao, N., Bagaria, H. G., Wong, M. S., and Zu, Y (2011). A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J. Nanobiotechnology 9,2.
121. Zhou, J., and Rossi, J. J. (2010). Aptamer-targeted cell-specific RNA interference. Silence 1,4.
122. Zhou, J., and Rossi, J. J. (2011). Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21, 1-10.